Patents by Inventor Clinton E. Canal
Clinton E. Canal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260337162Abstract: The present disclosure relates to tryptamine compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, polymorphs, or prodrugs thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT2 receptor agonists and uses in the treatment of diseases such as those diseases associated with a 5-HT2 receptor.Type: ApplicationFiled: August 23, 2023Publication date: October 29, 2026Applicant: Cybin IRL LimitedInventors: Alex Nivorozhkin, Joshua A. Hartsel, Clinton E. Canal, Tina A. Mueller, Kenneth L. Avery, Geoffrey B. Varty, Francesco G. Salituro, Michael Palfreyman
-
Patent number: 12767655Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.Type: GrantFiled: February 7, 2024Date of Patent: October 20, 2026Assignee: The Corporation of Mercer UniversityInventors: Clinton E. Canal, Nader Moniri, Yiming Chen
-
Publication number: 20260167603Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: ApplicationFiled: February 5, 2026Publication date: June 18, 2026Applicant: Cybin IRL LimitedInventors: Alex BELSER, Clinton E. CANAL, Brett J. GREENE, Joshua A. HARTSEL, Alex NIVOROZHKIN, Michael Palfreyman, Franesco SALITURO
-
Patent number: 12630504Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: GrantFiled: August 18, 2021Date of Patent: May 19, 2026Assignee: Cybin IRL LimitedInventors: Alex Belser, Clinton E. Canal, Brett J. Greene, Joshua A. Hartsel, Alex Nivorozhkin, Michael Palfreyman, Francesco Salituro
-
Publication number: 20250236589Abstract: There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.Type: ApplicationFiled: February 15, 2023Publication date: July 24, 2025Applicant: Cybin IRL LimitedInventors: Alex Nivorozhkin, Joshua A. Hartsel, Clinton E. Canal, Francesco G. Salituro, Tina A. Mueller, Brett J. Greene, Alex Belser, Kenneth L. Avery, Amy Claire Reichelt, Geoffrey B. Varty, Michael Palfreyman
-
Publication number: 20250145566Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin receptor or monoamine transporter, such as inflammation, central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: ApplicationFiled: February 15, 2023Publication date: May 8, 2025Applicant: Cybin IRL LimitedInventors: Alex Nivorozhkin, Joshua A. Hartsel, Clinton E. Canal, Francesco G. Salituro, Tina A. Mueller, Brett J. Greene, Alex Belser, Kenneth L. Avery, Amy Claire Reichelt, Geoffrey B. Varty, Michael Palfreyman
-
Publication number: 20240425451Abstract: There are disclosed deuterated 2C—X phenethylamine compounds. the use of such compounds in the treatment of diseases associated with a serotonin 5-HIT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds. methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: ApplicationFiled: September 5, 2024Publication date: December 26, 2024Applicant: Cybin IRL LimitedInventors: Alex Belser, Clinton E. Canal, Brett J. Greene, Joshua A. Hartsel, Alex Nivorozhkin, Michael Palfreyman
-
Patent number: 12122741Abstract: There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: GrantFiled: August 18, 2021Date of Patent: October 22, 2024Assignee: Cybin IRL LimitedInventors: Alex Belser, Clinton E. Canal, Brett J. Greene, Joshua A. Hartsel, Alex Nivorozhkin, Michael Palfreyman
-
Publication number: 20240317704Abstract: There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: ApplicationFiled: August 18, 2021Publication date: September 26, 2024Applicant: CYBIN IRL LIMITEDInventors: Alex BELSER, Clinton E. CANAL, Brett J. GREENE, Joshua A. HARTSEL, Alex NIVOROZHKIN, Michael PALFREYMAN, Francesco SALITURO
-
Publication number: 20240246973Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.Type: ApplicationFiled: February 7, 2024Publication date: July 25, 2024Inventors: Clinton E. Canal, Nader Moniri, Yiming Chen
-
Patent number: 11912705Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.Type: GrantFiled: August 20, 2021Date of Patent: February 27, 2024Assignee: The Corporation of Mercer UniversityInventors: Clinton E. Canal, Nader Moniri, Yiming Chen
-
Publication number: 20230312464Abstract: There are disclosed deuterated 2C—X phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.Type: ApplicationFiled: August 18, 2021Publication date: October 5, 2023Applicant: CYBIN IRL LIMITEDInventors: Alex BELSER, Clinton E. CANAL, Brett J. GREENE, Joshua A. HARTSEL, Alex NIVOROZHKIN, Michael PALFREYMAN
-
Publication number: 20220056029Abstract: Compounds, such as cathinone derivatives, and pharmaceutical formulations that include the compounds. The compounds may have a first selectivity for a first receptor subtype that is at least 10 times greater than a second selectivity for a second receptor subtype from the same class of receptors. Methods of treating patients, which may include administering to a patient a pharmaceutical formulation that includes a compound, such as a cathinone derivative.Type: ApplicationFiled: August 20, 2021Publication date: February 24, 2022Inventors: Clinton E. Canal, Nader Moniri, Yiming Chen